Prospects for a T-cell receptor vaccination against myasthenia gravis

References

• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 357, 2122–2128 (2001).
   PubMed Web of Science ®Google Scholar
• Vincent A. Unraveling the pathogenesis of myasthenia gravis. Natl Rev. Immunol.2, 797–804 (2002).
   PubMed Web of Science ®Google Scholar
• Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve23, 453–477 (2000).
   PubMed Web of Science ®Google Scholar
• Drachman DB. Myasthenia gravis. In: The Autoimmune Diseases. Rose NR, Mackay IP (Eds), San Diego, CA, USA. 637–662 (1998).
   Google Scholar
• Melms A, Chrestel S, Schalke BC et al. Autoimmune T-lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J. Clin. Invest.83, 785–790 (1989).
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Toyka KV, Heininger K, Grosse-Wilde H, Kalies I. Autoimmune human T-lymphocytes specific for acetylcholine receptor. Nature 310, 244–246 (1984).
   PubMed Web of Science ®Google Scholar
• Giraud M, Beaurain G, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Genetic control of autoantibody expression in autoimmune myasthenia gravis: role of the self-antigen and of HLA-linked loci. Genes Immun. 5, 398–404 (2004).
   PubMed Web of Science ®Google Scholar
• Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin. Neurol. 24, 125–133 (2004).
   PubMed Web of Science ®Google Scholar
• Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol.2, 99–106 (2003).
   PubMed Web of Science ®Google Scholar
• Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve25, 4–16 (2002).
   PubMed Web of Science ®Google Scholar
• Lindstrom J. Is ‘seronegative’ MG explained by autoantibodies to MuSK? Neurology62, 1920–1921 (2004).
   PubMed Web of Science ®Google Scholar
• Berrih-Aknin S, Cohen-Kaminsky S, Neumann D et al. Cellular aspects of myasthenia gravis. Immunol. Res.7, 189–199 (1988).
   PubMed Web of Science ®Google Scholar
• Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum. Pathol. 9, 495–515 (1978).
   PubMed Web of Science ®Google Scholar
• Vincent A. Aetiological factors in the development of myasthenia gravis. Adv. Neuroimmunol. 4, 355–371 (1994).
   PubMedGoogle Scholar
• Willcox N. Myasthenia Gravis. Curr. Opin. Immunol.5, 910–917 (1993).
   PubMed Web of Science ®Google Scholar
• Salmon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor α subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J. Clin. Invest. 101, 2340–2350 (1998).
   PubMed Web of Science ®Google Scholar
• Levinson AI, Wheatley LM. The thymus and the pathogenesis of myasthenia gravis. Clin. Immunol. Immunopathol. 78, 1–5 (1996).
   PubMedGoogle Scholar
• Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J. Immunol.157, 3752–3760 (1996).
   PubMed Web of Science ®Google Scholar
• Melms A, Schalke BC, Kirchner T, Muller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81, 902–908 (1988).
   PubMed Web of Science ®Google Scholar
• Truffault F, Cohen-Kaminsky S, Khalil I, Levasseur P, Berrih-Aknin S. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann. Neurol.41, 731–741 (1997).
   PubMed Web of Science ®Google Scholar
• Moulian N, Bidault J, Truffault F, Yamamoto AM, Levasseur P, Berrih-Aknin S. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood89, 3287–3295 (1997).
   PubMed Web of Science ®Google Scholar
• Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T-cells. Ann. Neurol.28, 312–319 (1990).
   PubMed Web of Science ®Google Scholar
• Fujii Y, Monden Y, Nakahara K, Hashimoto J, Kawashima Y. Antibody to acetylcholine receptor in myasthenia gravis: production by lymphocytes from thymus or thymoma. Neurology 34, 1182–1186 (1984).
   PubMed Web of Science ®Google Scholar
• Leprince C, Cohen-Kaminsky S, Berrih-Aknin S et al. Thymic B-cells from myasthenia gravis patients are activated B-cells. Phenotypic and functional analysis. J. Immunol.145, 2115–2122 (1990).
   PubMed Web of Science ®Google Scholar
• Berrih-Aknin S, Morel E, Raimond F et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann. NY Acad. Sci.505, 50–70 (1987).
   PubMed Web of Science ®Google Scholar
• Le Brigand H, Levasseur P, Miranda AR, Gaud C, Wojakowski I. Surgical treatment of myasthenia by thymectomy. A report on 248 cases. Sem. Hop. 56, 1502–1505 (1980).
   PubMedGoogle Scholar
• Molnar J, Szobor A. Myasthenia gravis: effect of thymectomy in 425 patients. A 15-year experience. Eur. J. Cardiothorac. Surg. 4, 8–14 (1990).
   PubMed Web of Science ®Google Scholar
• Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55, 7–15 (2000).
   PubMed Web of Science ®Google Scholar
• Jaretzki A, Barohn RJ, Ernstoff RM et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann. Thorac. Surg.70, 327–334 (2000).
   PubMed Web of Science ®Google Scholar
• Phillips LH. The epidemiology of myasthenia gravis. Semin. Neurol.24, 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain123(Pt. 4), 665–676 (2000).
   PubMed Web of Science ®Google Scholar
• Grob D. Natural history of myasthenia gravis. In: Myasthenia Gravis and Myasthenic Disorders. Engel AG (Ed.) Oxford, UK. 131–145 (1999).
   Google Scholar
• Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 61, 1652–1661 (2003).
   PubMed Web of Science ®Google Scholar
• Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56, 97–99 (2001).
   PubMed Web of Science ®Google Scholar
• Drachman DB. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve19, 1239–1251 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrero B, Durelli L. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol. Sci.23(Suppl. 1), S9–S24 (2002).
   PubMedGoogle Scholar
• Antozzi C. Myasthenia gravis and myasthenic syndrome. Neurol. Sci.24(Suppl.4), S260–S263 (2003).
   PubMedGoogle Scholar
• Engel AG. Congenital Myasthenic disorders. In: Myasthenis Gravis and Myasthenic Disorders. Engel AG (Ed), Oxford, 251–297 (1999).
   Google Scholar
• Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin. Neurol.23, 191–198 (2003).
   PubMed Web of Science ®Google Scholar
• Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol.41, 789–796 (1997).
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve22, 1479–1497 (1999).
   PubMed Web of Science ®Google Scholar
• Keesey JC. A history of treatments for myasthenia gravis. Semin. Neurol.24, 5–16 (2004).
   PubMed Web of Science ®Google Scholar
• Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin. Immunol. 94, 75–87 (2000).
   PubMed Web of Science ®Google Scholar
• Tzartos SJ, Barkas T, Cung MT et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev.163, 89–120 (1998).
   PubMed Web of Science ®Google Scholar
• Berrih-Aknin S, Cohen-Kaminsky S, Lepage V, Neumann D, Bach JF, Fuchs S. T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J. Autoimmun. 4, 137–153 (1991).
   PubMed Web of Science ®Google Scholar
• Protti MP, Manfredi AA, Horton RM, Bellone M, Conti-Tronconi BM. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today.14, 363–368 (1993).
   PubMedGoogle Scholar
• Weiner HL. Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis. J. Clin. Invest. 104, 1667–1668 (1999).
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Fuchs S, Souroujon MC. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest.104, 1723–1730 (1999).
   PubMed Web of Science ®Google Scholar
• Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152, 112–120 (2004).
   PubMed Web of Science ®Google Scholar
• Pachner AR. Antigen-specific immunotherapy in myasthenia gravis: failed promise and new hope. J. Neuroimmunol.152, vii–viii (2004).
   PubMedGoogle Scholar
• Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit. Rev. Immunol.20, 1–16 (2000).
   PubMed Web of Science ®Google Scholar
• Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73, 153–264 (1999).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167–1175 (2000).
   Google Scholar
• Weathington NM, Blalock JE. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Expert Rev. Vaccines 2, 61–73 (2003).
   PubMedGoogle Scholar
• Pendergraft WF III, Preston GA, Shah RR et al. Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3. Nature Med. 10, 72–79 (2004).
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Hashim GA, Offner H. T-cell receptor peptides in treatment of autoimmune disease: rationale and potential. J. Neurosci. Res. 43, 391–402 (1996).
   PubMed Web of Science ®Google Scholar
• Gigliotti D, Lefvert AK, Jeddi-Tehrani M et al. Overexpression of select T-cell receptor V beta gene families within CD4+ and CD8+ T-cell subsets of myasthenia gravis patients: a role for superantigen(s)? Mol. Med. 2, 452–459 (1996).
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Oksenberg JR, Baggi F et al. Increased incidence of certain TCR and HLA genes associated with myasthenia gravis in Italians. J. Autoimmun. 3, 431–440 (1990).
   PubMed Web of Science ®Google Scholar
• Grunewald J, Ahlberg R, Lefvert AK, DerSimonian H, Wigzell H, Janson CH. Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients. Scand. J. Immunol. 34, 161–168 (1991).
   PubMed Web of Science ®Google Scholar
• Willcox N, Baggi F, Batocchi AP et al. Approaches for studying the pathogenic T-cells in autoimmune patients. Ann. NY Acad. Sci.681, 219–237 (1993).
   PubMed Web of Science ®Google Scholar
• Melms A, Oksenberg JR, Malcherek G et al. T-cell receptor gene usage of acetylcholine receptor-specific T-helper cells. Ann. NY Acad. Sci.681, 313–314 (1993).
   PubMed Web of Science ®Google Scholar
• Raju R, Navaneetham D, Protti MP et al. Acetylcholine receptor-specific CD4+ T-cells in myasthenia gravis patients have individual, but restricted TCR V beta usage. Ann. NY Acad. Sci.841, 324–328 (1998).
   PubMed Web of Science ®Google Scholar
• Infante AJ, Baillargeon J, Kraig E et al. Evidence of a diverse T-cell receptor repertoire for acetylcholine receptor, the autoantigen of myasthenia gravis. J. Autoimmun.21, 167–174 (2003).
   PubMed Web of Science ®Google Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature Rev. Immunol.2, 85–95 (2002).
   PubMed Web of Science ®Google Scholar
• Aissaoui A, Klingel-Schmitt I, Couderc J et al. Prevention of autoimmune attack by targeting specific T-cell receptor in a SCID mice model of myasthenia gravis. Ann. Neurol. 46, 559–567 (1999).
   PubMed Web of Science ®Google Scholar
• Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain103, 579–601 (1980).
   PubMed Web of Science ®Google Scholar
• Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J. Neuroimmunol. 47, 115–122 (1993).
   PubMed Web of Science ®Google Scholar
• Jambou F, Zhang W, Menestrier M et al. Circulating regulatory anti-TCR antibodies in patients with myasthenia gravis. J. Clin. Invest. 112, 265–274 (2003).
   PubMed Web of Science ®Google Scholar
• Jambou F, Menestrier M, Klingel-Schmitt I et al. Rationale for a T-cell receptor peptide therapy in Myasthenia Gravis. Ann. NY Acad. Sci. USA. 988, 320–323 (2003).
   Google Scholar
• Jambou F, Cohen-Kaminsky S. Immunoregulation by Vβ specific antibodies in myasthenia gravis: mining physiological T-cell homeostasis for TCR specific therapy. Cell Mol. Biol. (Noisy-le-grand) 181–192 (2003).
   PubMed Web of Science ®Google Scholar
• Kahn CR, McIntosh KR, Drachman DB. T-cell vaccination in experimental myasthenia gravis: a double-edged sword. J. Autoimmun.3, 659–669 (1990).
   PubMed Web of Science ®Google Scholar
• Sela M, Arnon R, Schechter B. Therapeutic vaccines: realities of today and hopes for the future. Drug Discov. Today.7, 664–673 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen IR. T-cell vaccination for autoimmune disease: a panorama. Vaccine20, 706–710 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar V, Coulsell E, Ober B, Hubbard G, Sercarz E, Ward ES. Recombinant T-cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis: dose effects and involvement of both CD4 and CD8 T-cells. J. Immunol.159, 5150–5156 (1997).
   PubMed Web of Science ®Google Scholar
• Offner H, Adlard K, Bebo BF Jr et al. Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice. J. Immunol.161, 2178–2186 (1998).
   PubMed Web of Science ®Google Scholar
• Waisman A, Ruiz PJ, Hirschberg DL et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 Immunity Nature Med. 2, 899–905 (1996).
   PubMed Web of Science ®Google Scholar
• Kumar V, Sercarz E. Genetic vaccination: the advantages of going naked. Nature Med. 2, 857–859 (1996).
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Jee Y, Sugisaki M. Successful TCR-based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR. J. Immunol.164, 2248–2254 (2000).
   PubMed Web of Science ®Google Scholar
• Braciak TA, Pedersen B, Chin J et al. Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the Vβ 8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or -10. J. Immunol.170, 765–774 (2003).
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Morgan E, Bartholomew R et al. TCR peptide therapy in human autoimmune diseases. Neurochem. Res.26, 713–730 (2001).
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Chou YK, Whitham R et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Med. 2, 1109–1115 (1996).
   PubMed Web of Science ®Google Scholar
• Hellings N, Raus J, Stinissen P. T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun. Rev.3, 267–275 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar V, Sercarz E, Zhang J, Cohen I. T-cell vaccination: from basics to the clinic. Trends Immunol. 22, 539–540 (2001).
   PubMedGoogle Scholar
• Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis. Expert Rev. Vaccines1, 285–292 (2002).
   PubMedGoogle Scholar
• Cohen IR. Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia45, 1468–1474 (2002).
   PubMed Web of Science ®Google Scholar
• Lambert SL, Okada CY, Levy R. TCR vaccines against a murine T-cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J. Immunol.172, 929–936 (2004).
   PubMed Web of Science ®Google Scholar
• Husband AJ, Bao S, McClure SJ, Emery DL, Ramsay AJ. Antigen delivery strategies for mucosal vaccines. Int. J. Parasitol.26, 825–834 (1996).
   PubMed Web of Science ®Google Scholar
• Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol.14, 666–672 (2002).
   PubMed Web of Science ®Google Scholar
• Bourdette DN, Whitham RH, Chou YK et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ 5.2 and Vβ 6.1 CDR2 peptides. J. Immunol.152, 2510–2519 (1994).
   PubMed Web of Science ®Google Scholar
• Chou YK, Morrison WJ, Weinberg AD et al. Immunity to TCR peptides in multiple sclerosis. II. T-cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. J. Immunol. 152, 2520–2529 (1994).
   PubMed Web of Science ®Google Scholar
• Haqqi TM, Qu XM, Anthony D, Ma J, Sy MS. Immunization with T-cell receptor V beta chain peptides deletes pathogenic T-cells and prevents the induction of collagen-induced arthritis in mice. J. Clin. Invest. 97, 2849–2858 (1996).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Heck LW Jr, Koopman WJ et al. V beta 17 T-cell receptor peptide vaccination in rheumatoid arthritis: results of Phase I dose escalation study. J. Rheumatol. 23, 1353–1362 (1996).
   PubMed Web of Science ®Google Scholar
• Bridges SL Jr, Moreland LW. T-cell receptor peptide vaccination in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24, 641–650 (1998).
   PubMed Web of Science ®Google Scholar
• Garren H, Ruiz PJ, Watkins TA et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity15, 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar V, Sercarz E. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol. Rev.182, 113–121 (2001).
   PubMed Web of Science ®Google Scholar
• Sercarz E, Maverakis E, van den Elzen P, Madakamutil L, Kumar V. Seven surprises in the TCR-centred regulation of immune responsiveness in an autoimmune system. Novartis Found. Symp. 252, 165–171 (2003).
   PubMedGoogle Scholar
• Madakamutil LT, Maricic I, Sercarz E, Kumar V. Regulatory T-cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol.170, 2985–2992 (2003).
   PubMed Web of Science ®Google Scholar
• Hermans G, Denzer U, Lohse A, Raus J, Stinissen P. Cellular and humoral immune responses against autoreactive T-cells in multiple sclerosis patients after T-cell vaccination. J. Autoimmun. 13, 233–246 (1999).
   PubMed Web of Science ®Google Scholar
• Honda A, Ametani A, Matsumoto T et al. Vaccination with an immunodominant peptide of bovine Type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int. Immunol.16, 737–745 (2004).
   PubMed Web of Science ®Google Scholar
• Elias D, Tikochinski Y, Frankel G, Cohen IR. Regulation of NOD mouse autoimmune diabetes by T-cells that recognize a TCR CDR3 peptide. Int. Immunol.11, 957–966 (1999).
   PubMed Web of Science ®Google Scholar
• Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T-cells. Adv. Immunol.81, 331–371 (2003).
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Hicks K, Tsaknaridis L et al. Regulation of autoimmunity with TCR peptides: latest breakthroughs. 6th International Symposium on the Immunotherapy of the Rheumatic Disesases. Cyprus (2002).
   Google Scholar
• Balandina A, Lécart S, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4+ CD25+ T-cells in the thymus of patients with autoimmune myasthenia gravis. Blood105, 735–741 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar V. Homeostatic control of immunity by TCR peptide-specific Tregs. J. Clin. Invest.114, 1222–1226 (2004).
   PubMed Web of Science ®Google Scholar
• Buenafe AC, Tsaknaridis L, Spencer L et al. Specificity of regulatory CD4+ CD25+ T-cells for self-T-cell receptor determinants. J. Neurosci. Res. 76, 129–140 (2004).
   PubMed Web of Science ®Google Scholar
• Liu HY, Buenafe AC, Matejuk A et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70, 238–248 (2002).
   PubMed Web of Science ®Google Scholar
• Polanczyk MJ, Carson BD, Subramanian S et al. Cutting edge: estrogen drives expansion of the CD4+ CD25+ regulatory T-cell compartment. J. Immunol.173, 2227–2230 (2004).
   PubMed Web of Science ®Google Scholar
• Offner H, Adlard K, Zamora A, Vandenbark AA. Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J. Clin. Invest.105, 1465–1472 (2000).
   PubMed Web of Science ®Google Scholar
• Herkel J, Brunner S, Meyer zum Buschenfelde KH, Lohse AW. Humoral mechanisms in T-cell vaccination: induction and functional characterization of antilymphocytic autoantibodies. J. Autoimmun. 10, 137–146 (1997).
   PubMed Web of Science ®Google Scholar
• Hong J, Zang YC, Tejada-Simon MV et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T-cell vaccination. J. Immunol.165, 6858–6864 (2000).
   PubMed Web of Science ®Google Scholar
• Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70, 849–860 (2001).
   PubMed Web of Science ®Google Scholar
• Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines2, 305–315 (2003).
   PubMedGoogle Scholar
• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol.84, 223–243 (1997).
   PubMedGoogle Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun. Rev.2, 119–125 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan EE, Nardo CJ, Diveley JP et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J. Neurosci. Res. 64, 298–301 (2001).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Morgan EE, Adamson TC III et al. T-cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides. Arthritis Rheum.41, 1919–1929 (1998).
   PubMed Web of Science ®Google Scholar
• Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor β chains vary as a function of the recombined germ-line segments. Proc. Natl Acad. Sci. USA90, 4319–4323 (1993).
   PubMed Web of Science ®Google Scholar
• Pasqual N, Gallagher M, Aude-Garcia C et al. Quantitative and qualitative changes in V-J α rearrangements during mouse thymocytes differentiation: implication for a limited T-cell receptor α chain repertoire. J. Exp. Med.196, 1163–1173 (2002).
   PubMed Web of Science ®Google Scholar
• Muraro PA, Jacobsen M, Necker A et al. Rapid identification of local T-cell expansion in inflammatory organ diseases by flow cytometric T-cell receptor Vβ analysis. J. Immunol. Methods246, 131–143 (2000).
   PubMed Web of Science ®Google Scholar
• Guillet M, Sebille F, Soulillou J. TCR usage in naive and committed alloreactive cells: implications for the understanding of TCR biases in transplantation. Curr. Opin. Immunol. 13, 566–571 (2001).
   PubMed Web of Science ®Google Scholar
• Steinman L. Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed (with a hedge on this bet). J. Autoimmun.14, 278–282 (2000).
   PubMed Web of Science ®Google Scholar
• Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol. Rev.164, 157–168 (1998).
   PubMed Web of Science ®Google Scholar
• Xu L, Villain M, Galin FS, Araga S, Blalock JE. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T-cells. Cell Immunol. 208, 107–114 (2001).
   PubMed Web of Science ®Google Scholar
• Villinger F. Cytokines as clinical adjuvants: how far are we? Expert Rev. Vaccines2, 317–326 (2003).
   PubMedGoogle Scholar